The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma

Sarah B. Whittle, Kalyani Patel, Linna Zhang, Sarah E. Woodfield, Michael du, Valeria Smith, Peter Zage

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes. Ponatinib is a multi-tyrosine kinase inhibitor that targets many pathways implicated in neuroblastoma pathogenesis. We hypothesized that ponatinib would be effective against neuroblastoma in preclinical models. Methods We evaluated the effects of ponatinib on survival and migration of human neuroblastoma cells in vitro. Using orthotopic xenograft mouse models of human neuroblastoma, we analyzed tumors treated with ponatinib for growth, gross and histologic appearance, and vascularity. Results Ponatinib treatment of neuroblastoma cells resulted in decreased cell viability and migration in vitro. In mice with orthotopic xenograft neuroblastoma tumors, treatment with ponatinib resulted in decreased growth and vascularity. Conclusions Ponatinib reduces neuroblastoma cell viability in vitro and reduces tumor growth and vascularity in vivo. The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma, and further preclinical testing is warranted.

Original languageEnglish (US)
Pages (from-to)685-692
Number of pages8
JournalInvestigational New Drugs
Issue number6
StatePublished - Dec 1 2016


  • Angiogenesis
  • Migration
  • Neuroblastoma
  • Ponatinib
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma'. Together they form a unique fingerprint.

Cite this